ResearchNIH-Funded Study Cuts New HIV Infections by 70% in Rural Kenya and Uganda U... NIH-Funded Study Cuts New HIV Infections by 70% in Rural Kenya and Uganda U... Read Post »
ResearchNIH Identifies Novel Opioid Candidate with Strong Analgesia and Reduced Add... NIH Identifies Novel Opioid Candidate with Strong Analgesia and Reduced Add... Read Post »
New Drug ApprovalMHRA Approves Sevabertinib for HER2+ Lung Cancer MHRA Approves Sevabertinib for HER2+ Lung Cancer Read Post »
Clinical TrialsPriovant Expands Brepocitinib Development Program with Initiation of Phase ... Priovant Expands Brepocitinib Development Program with Initiation of Phase ... Read Post »
New Drug ApprovalEU Approves First PD-1–Based Regimen KEYTRUDA for Platinum-Resistant Ovar... EU Approves First PD-1–Based Regimen KEYTRUDA for Platinum-Resistant Ovar... Read Post »
ResearchSemaglutide Recommended by NICE as Add-On Option to Reduce Risk of Heart At... Semaglutide Recommended by NICE as Add-On Option to Reduce Risk of Heart At... Read Post »
New Drug ApprovalRegeneron Pharmaceuticals Secures FDA Nod for Extended EYLEA HD Dosing Up t... Regeneron Pharmaceuticals Secures FDA Nod for Extended EYLEA HD Dosing Up t... Read Post »
New Drug ApprovalFDA Converts Tecartus Approval to Full Approval in Mantle Cell Lymphoma Fol... FDA Converts Tecartus Approval to Full Approval in Mantle Cell Lymphoma Fol... Read Post »
Clinical TrialsBridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... BridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... Read Post »
Clinical TrialsImfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Imfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Read Post »
Clinical TrialsInnovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Innovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Read Post »
Clinical TrialsNovo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Novo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Read Post »
Clinical TrialsInnovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Innovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Read Post »
Clinical TrialsPepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study PepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study Read Post »
New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Lilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Read Post »
Clinical TrialsOcugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Ocugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Read Post »
Drugs Safety AlertFDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) FDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) Read Post »
Clinical TrialsAstra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Astra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Read Post »
Clinical TrialsConnect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Connect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Read Post »
Clinical TrialsUnited Therapeutics’ Tyvaso Surpasses TETON-2 with Strong TETON-1 IPF Res... United Therapeutics’ Tyvaso Surpasses TETON-2 with Strong TETON-1 IPF Res... Read Post »
Clinical TrialsMerck’s Oral PCSK9 Candidate Enlicitide Cuts LDL-C by 64.6% in Phase 3 Ad... Merck’s Oral PCSK9 Candidate Enlicitide Cuts LDL-C by 64.6% in Phase 3 Ad... Read Post »
Clinical TrialsTanabe’s Dersimelagon Improves Sunlight Tolerance in Phase 3 Study in Rar... Tanabe’s Dersimelagon Improves Sunlight Tolerance in Phase 3 Study in Rar... Read Post »
Clinical TrialsWith 3-Dose Regimen, Viridian’s Elegrobart Shows Breakthrough Potential i... With 3-Dose Regimen, Viridian’s Elegrobart Shows Breakthrough Potential i... Read Post »
Clinical TrialsConnect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Connect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Read Post »
Clinical TrialsBeyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Beyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Read Post »
Clinical TrialsBMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... BMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... Read Post »
New Drug ApprovalBiogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Biogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Read Post »
Clinical TrialsBiogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Biogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Read Post »
ResearchCorcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Corcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Read Post »
Clinical TrialsTakeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Read Post »
Clinical TrialsIncyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Incyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Read Post »
Clinical TrialsTaltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Taltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Read Post »
Clinical TrialsLilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Lilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Read Post »
Clinical TrialsSanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Sanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Read Post »
Clinical TrialsLenvima, Welireg Moves Closer to Approval with Japan Submission Lenvima, Welireg Moves Closer to Approval with Japan Submission Read Post »
New Drug ApprovalCHMP Recommends Five New Medicines for EU Approval in March 2026 CHMP Recommends Five New Medicines for EU Approval in March 2026 Read Post »
Clinical TrialsAstraZeneca Reports Positive Phase III Data for Tozorakimab in COPD AstraZeneca Reports Positive Phase III Data for Tozorakimab in COPD Read Post »
New Drug ApprovalChina Approves ENHERTU as First HER2 ADC for Neoadjuvant Breast Cancer China Approves ENHERTU as First HER2 ADC for Neoadjuvant Breast Cancer Read Post »
Clinical TrialsWave’s RNA Therapy WVE-007 Shows Early Fat-Loss Signal in INLIGHT Trial Wave’s RNA Therapy WVE-007 Shows Early Fat-Loss Signal in INLIGHT Trial Read Post »
New Drug ApprovalNovo Nordisk Wins FDA Approval for Once-Weekly Basal Insulin Awiqli Novo Nordisk Wins FDA Approval for Once-Weekly Basal Insulin Awiqli Read Post »
New Drug ApprovalFDA Grants Accelerated Approval to Rocket’s Kresladi Gene Therapy for... FDA Grants Accelerated Approval to Rocket’s Kresladi Gene Therapy for... Read Post »
Clinical TrialsEncoded Aligns with FDA on Pivotal ENDEAVOR Trial Design for ETX101 in Drav... Encoded Aligns with FDA on Pivotal ENDEAVOR Trial Design for ETX101 in Drav... Read Post »
Clinical TrialsCompass Updates COMP360 Pipeline, Targets FDA Filing in TRD Compass Updates COMP360 Pipeline, Targets FDA Filing in TRD Read Post »
New Drug ApprovalCorcept’s Relacorilant Combo Approved for Resistant Ovarian Cancer Corcept’s Relacorilant Combo Approved for Resistant Ovarian Cancer Read Post »
New Drug ApprovalFDA Clears Denali’s AVLAYAH, First Brain-Penetrant Therapy for Hunter... FDA Clears Denali’s AVLAYAH, First Brain-Penetrant Therapy for Hunter... Read Post »
Clinical TrialsInnovent Reports Positive Phase 3 Data for IBI302 in Wet AMD Innovent Reports Positive Phase 3 Data for IBI302 in Wet AMD Read Post »
Clinical TrialsSarepta Advances siRNA Pipeline with Early FSHD and DM1 Trial Data Sarepta Advances siRNA Pipeline with Early FSHD and DM1 Trial Data Read Post »
Clinical TrialsNovo Nordisk, TUL Report Positive UBT251 Phase 2 Results Novo Nordisk, TUL Report Positive UBT251 Phase 2 Results Read Post »
Clinical TrialsOcugen’s OCU410 Demonstrates 31% Lesion Reduction in Phase 2 GA Trial Ocugen’s OCU410 Demonstrates 31% Lesion Reduction in Phase 2 GA Trial Read Post »
Drugs Safety AlertAardvark Halts ARD-101 and ARD-201 Studies After QRS Signal in Safety Study Aardvark Halts ARD-101 and ARD-201 Studies After QRS Signal in Safety Study Read Post »
